Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
Articles
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Why Microdosing Cannot Replace Psychedelic Medicine
Psychedelic medicine is proving it can provide spectacular treatment results for many mental health disorders. Microdosing may also be an important therapy tool. But there's a catch.
Revitalist Receives Approval from Biomedical Research Alliance of New York Permitting the Company to Perform Human Subjects Clinical Trials
Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and "repeated transcranial magnetic stmulation" treatments (rTMS).
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
COMPASS Pathways reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business.
Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements
Optimi Health announces the launch of six nootropic supplements derived from functional mushrooms.
The Future of Psychedelic Medicine: Two DIFFERENT Treatment Models
Spiritual journey or clinical therapy? What does the future of psychedelic medicine look like?
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
Mindset announces new insights in research on psychedelics molecules via its COPE initiative.
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
Pharmather announces a method of use and composition of matter patent from the USPTO for its proprietary ketamine formulation, KETABET(TM).
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
Optimi Health's subsidiary has been named an approved supplier of psilocybin for Health Canada's SAP access program.
Novamind Advances Clinical Pilot for Frontline KAP
Novamind announces a "clinical pilot" aimed at bringing ketamine-assisted therapy to treat the mental health disorders of frontline healthcare workers.
Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update
During the quarter, Field Trip progressed its strategy of building the leading psychedelic therapy company through its Field Trip Health division and continued to invest in its lead drug development program.
Hawaii Senators Approve Psilocybin Task Force Bill In Committee, With Decriminalization Measures Still Pending
A Hawaii Senate committee on Friday approved a bill to set up a state working group to study the therapeutic benefits of psilocybin mushrooms.